FibroGen (NASDAQ:FGEN) Sees Unusually-High Trading Volume


Share on StockTwits

Shares of FibroGen, Inc. (NASDAQ:FGEN) saw an uptick in trading volume on Thursday . 60,416 shares changed hands during trading, a decline of 95% from the previous session’s volume of 1,252,101 shares.The stock last traded at $18.95 and had previously closed at $19.74.

Several equities analysts have recently weighed in on FGEN shares. Bank of America upgraded shares of FibroGen from a “neutral” rating to a “buy” rating and set a $47.00 price objective on the stock in a report on Wednesday, March 31st. JPMorgan Chase & Co. upgraded shares of FibroGen to a “neutral” rating in a report on Wednesday. HC Wainwright lowered shares of FibroGen from a “buy” rating to a “neutral” rating in a report on Wednesday. Jefferies Financial Group reiterated a “hold” rating and set a $45.00 price objective (down previously from $75.00) on shares of FibroGen in a report on Monday, March 8th. Finally, Raymond James restated a “sell” rating on shares of FibroGen in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $46.14.

The stock’s 50-day moving average price is $38.93 and its two-hundred day moving average price is $42.24. The stock has a market capitalization of $1.74 billion, a P/E ratio of -7.56 and a beta of 1.59.

FibroGen (NASDAQ:FGEN) last released its earnings results on Sunday, February 28th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.35). The company had revenue of $65.00 million for the quarter, compared to the consensus estimate of $100.82 million. FibroGen had a negative net margin of 191.78% and a negative return on equity of 48.19%. The firm’s revenue was up 712.5% on a year-over-year basis. During the same period in the prior year, the company earned ($1.12) earnings per share. On average, sell-side analysts predict that FibroGen, Inc. will post -1.72 EPS for the current year.

In related news, Director Thomas F. Kearns, Jr. sold 18,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 11th. The shares were sold at an average price of $35.02, for a total value of $630,360.00. Following the completion of the transaction, the director now directly owns 166,164 shares of the company’s stock, valued at approximately $5,819,063.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kalevi Kurkijarvi sold 6,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 19th. The stock was sold at an average price of $43.38, for a total transaction of $260,280.00. Following the completion of the transaction, the director now directly owns 39,100 shares of the company’s stock, valued at $1,696,158. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,999 shares of company stock valued at $1,445,240. 3.39% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Perigon Wealth Management LLC purchased a new stake in FibroGen in the 4th quarter worth approximately $46,000. Fieldpoint Private Securities LLC purchased a new stake in FibroGen in the 4th quarter worth approximately $65,000. Penserra Capital Management LLC lifted its stake in FibroGen by 170.1% in the 4th quarter. Penserra Capital Management LLC now owns 2,085 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 1,313 shares in the last quarter. Sowell Financial Services LLC lifted its stake in FibroGen by 895.0% in the 4th quarter. Sowell Financial Services LLC now owns 2,806 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 2,524 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its stake in FibroGen by 17.3% in the 4th quarter. Pacer Advisors Inc. now owns 3,228 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 476 shares in the last quarter. Institutional investors and hedge funds own 75.05% of the company’s stock.

FibroGen Company Profile (NASDAQ:FGEN)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.

Read More: Dividend Yield

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.